Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer

International Journal of Gynecological Cancer

Volumn 13, Issue 4, 2003, Pages 548-550

  Abali, Hüseyin ^a   Eren, O O ^a   Erman, M ^a   Uner, A H ^a   Kose, F ^b   Guler, N ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Social Security Hospital   (Turkey)

Author keywords

Cervical squamous cell carcinoma; Human immunodeficiency virus; Non Hodgkin's Lymphoma; Therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYSTERECTOMY; LYMPH NODE DISSECTION; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; UTERINE CERVIX CANCER; VAGINA BLEEDING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA, B-CELL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PREDNISONE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; T-LYMPHOCYTES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VINCRISTINE;

EID: 1242339564     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13310.x     Document Type: Article

References (15)

1. Robinson W. Invasive and preinvasive cervical neoplasm in human immunodeficiency virus-infected women. Semin Oncol 2000;27:463-70.
2. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27:390-401.
3. Ayhan A, Tuncer ZS. Radical hysterectomy with lymphadenectomy for treatment of early stage cervical cancer: Clinical experience of 278 cases. J Surg Oncol 1991;47:175-7.
4. Moore DH. Chemoradiation and controversies in stage 1B cervical cancer. In: Perry MC, ed. Proceedings of the Annual Meeting of American Society of Clinical Oncology Educational Book. Orlando: American Society of Clinical Oncology, 2002:453-8.
5. Larson DM, Stringer SA, Copeland LJ. Stage IB cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy role of adjuvant radiotherapy. Obstet Gynecol 1987;69:378-81.
6. Peters WA 3rd, Liu PY, Barrett RJ 2nd et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
7. Morris M, Eifel PJ, Ju J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic for high-risk cervical cancer. N Eng J Med 1999;340:1137-43.
8. Eifel PJ. Chemoradiation for carcinoma of the cervix: Advances and opportunities. Radiat Res 2000;154:229-36.
9. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomittant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781-6.
10. Fisher R, Gaynor E, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
11. Barista I, Tekuzman G, Firat D et al. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University. Jpn J Cancer Res 1994;85:1200-7.
12. Yalcin S, Kars A, Ozisik Y et al. VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas. Eur J Haematol 1998;61:261-5.
13. Ozturk MA, Barista I, Altundag MK et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma. Results of a single-center study of 32 patients. Chemotherapy 2002;48:252-8.
14. Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol 2001;40:224-30.
15. Kewalramani T, Moskowitz CH. Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits? Curr Oncol Rep 2001;3:271-8.